Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase I/IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effects After Intravenous Transplantation of Human Umbilical Cord-derived Mesenchymal Stem Cells in Patients With Cerebral Infarction Disease
NCT02378974 is registered in ClinicalTrials.gov with CHABiotech CO., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Phase I/IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effects After Intravenous Transplantation of Human Umbilical Cord-derived Mesenchymal Stem Cells in Patients With Cerebral Infarction Disease
- Lead sponsor
- CHABiotech CO., Ltd
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 28, 2015
- Completion date
- April 30, 2017
- Enrollment
- 18 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.